Note 8 - Leases

6 Months Ended

Jun. 30, 2022

Notes to Financial Statements

Lessee, Operating Leases [Text Block]

8. Leases

We conduct the majority of our operations in leased facilities, all of which are accounted for as operating leases, as they do not meet the criteria for finance leases. Our principal worldwide executive, distribution, and manufacturing operations are located in five leased facilities with square footage totaling 109,354 in Burlington, Massachusetts. All five Burlington leases expire in December 2030.

Our European operations are headquartered at a 21,410 square foot leased facility located in Sulzbach, Germany. During the quarter ended June 30, 2022 we increased our square footage by 4,940 (from 16,470) and extended the lease through June 2031. This lease contains a five-year renewal option. Additionally, during the quarter ending June 30, 2022, we signed a new sales office/warehouse lease in the Seoul, Korea, which includes 2,300 square feet of office space, and expires in April 2027. Finally, we extended our Singapore lease by one-year and it will expire in June 2023.

Similar to prior quarters, we also lease a facility in Hereford, England which houses our United Kingdom sales and distribution business. During the quarter ended June 30, 2021 we executed an expansion of the Hereford lease under terms substantially similar to the original lease. In connection with our acquisition of the Artegraft biologic graft business, we assumed a 16,732 square foot lease in North Brunswick, New Jersey, which expires in October 2029. In June 2021 we entered into a six-year lease in Milan, Italy which houses a customer service and warehouse facility. This lease contains a six-year renewal option. We also have smaller long-term leased sales, marketing and other facilities located in Arizona, Canada, Australia, Singapore and China, and short-term leases in Japan, Spain and Illinois. The lease in Arizona was extended during the quarter ending June 30, 2022, for an additional three years through August 2025, effective as of August 24, 2022. Our lease in Canada contains a five-year renewal option exercisable in February 2023. Our leases in Germany and Italy are subject to periodic rent increases based on increases in the consumer price index as measured on an annual basis, with such increases applicable to the subsequent twelve months of lease payments. None of our noncancelable lease payments include non-lease components such as maintenance contracts; we generally reimburse the landlord for direct operating costs associated with the leased space. We have no subleases, and there are no residual value guarantees associated with, or restrictive covenants imposed by, any of our leases. There were no assets held under capital leases at June 30, 2022.

We also lease automobiles under operating leases in the United States as well as certain of our international subsidiaries. The terms of these leases are generally three years, with older vehicles replaced by newer vehicles from time to time. During the fiscal year 2021, we entered into a five-year lease for printing equipment.

We account for leases under the provisions of ASU No. 2016-02, Leases (Topic 842), subsequently amended by ASU 2018-11, Leases (Topic 842): Targeted Improvements. Under this guidance, we are required to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term.

Our most significant judgment involved in determining the amounts to initially record as lease liabilities and right-of-use assets upon initial adoption of this standard, and for leases entered into subsequently, was the selection of a discount rate; because we had no debt as of the adoption of this standard, we had no incremental borrowing rate to reference. We therefore derived an incremental borrowing rate using quotes from potential lenders as the primary inputs, augmented by other available information. The resulting rate selected was 5.25%. We determined that it was appropriate to apply this single rate to our portfolio of leases worldwide, as the lease terms and conditions are substantially similar, and because we believe our subsidiaries would be unable to obtain borrowings on their own without a commitment of parent company support. In connection with the assumption of the Artegraft North Brunswick, New Jersey lease, we used LeMaitre’s borrowing rate of 3.5% as of the acquisition date associated with debt incurred to finance the acquisition to value the lease.

Additional information with respect to our leases is as follows:

	Three months ended June 30,				Six months ended June 30,
	2022		2021		2022			2021
	(in thousands)		(in thousands)		(in thousands)			(in thousands)
Lease cost
Operating lease cost	$	638	$	487	$	1,163		$	1,094
Short-term lease cost		161		126		324			190
Total lease cost	$	799	$	613	$	1,487		$	1,284
Other information
Cash paid for amounts included in the  measurement of operating lease liabilities	$	810	$	633	$	1,484		$	1,381
Right-of-use assets obtained in exchange for new operating lease liabilities	$	2,240	$	1,261	$	2,381		$	1,277
Weighted average remaining lease term -  operating leases (in years)						8.2			8.2
Weighted average discount rate -  operating leases						4.88	%		4.86	%

At June 30, 2022, the minimum non-cancelable operating lease rental commitments with initial or remaining terms of more than one year are as follows:

Remainder of 2022	$	1,463
Year ending December 31,
2023		2,602
2024		2,547
2025		2,530
2026		2,489
2027		2,372
Thereafter		6,973
Adjustment to net present value as of June 30, 2022		(3,762	)
Minimum noncancelable lease liability	$	17,214